Fresenius SE

Investor News 2007

21.12.2007Fresenius Biotech applies for the marketing authorization of the trifunctional antibody Removab® for the treatment of malignant ascites
PDF Text as PDF-File
11.12.2007Fresenius Kabi acquires leading European manufacturer of antibiotic agents and strengthens its position in the area of intravenously administered generic drugs
PDF Text as PDF-File
07.12.2007Fresenius Kabi expands infusion therapy business in Latin America
PDF Text as PDF-File
26.11.2007Fresenius Kabi continues growth strategy and strengthens its Clinical Nutrition business
PDF Text as PDF-File
22.11.2007HELIOS continues expansion in the German hospital market and acquires the Krefeld Municipal Hospitals
PDF Text as PDF-File
31.10.2007Q1-3 2007: Excellent sales and earnings growth in all business segments – Strong third quarter – Outlook raised
(for additional tables please see pdf-file)
PDF Text as PDF-File
02.08.2007First half 2007: Fresenius reports continued growth in sales and earnings and raises full-year earnings outlook
(for additional tables please see pdf-file)
PDF Text as PDF-File
17.07.2007Secondary endpoints of phase II/III study confirm clear benefits from treatment with removab® for patients with malignant ascites
PDF Text as PDF-File
16.07.2007Fresenius completes conversion into a European Company (SE)
PDF Text as PDF-File
06.06.2007Fresenius streamlines hospital business structure and announces changes to the Management Board
PDF Text as PDF-File
02.05.2007Q1 2007: Successful start to 2007
(for additional tables please see pdf-file)
PDF Text as PDF-File
25.04.2007Fresenius Kabi to acquire blood volume replacement business of Japanese pharmaceutical company Kyorin
PDF Text as PDF-File
02.04.2007Fresenius ProServe completes the divestiture of Pharmaplan GmbH
PDF Text as PDF-File
22.03.2007Phase II/III pivotal study with trifunctional antibody removab® shows encouraging results in malignant ascites from various cancers
PDF Text as PDF-File
22.02.2007Outstanding 2006 financial results – Financial targets exceeded
Positive outlook for 2007: Sales to increase by 8 to 10 %, net income to grow by 20 to 25 %
(for additional tables please see pdf-file)
PDF Text as PDF-File
22.02.2007Consolidated Balance Sheet as PDF-file
22.02.2007Consolidated Profit and Loss Statement as PDF-file
22.02.2007Consolidated Cash Flow Statement as PDF-file
30.01.2007Fresenius share split to become effective
PDF Text as PDF-File
Home  >  Investor Relations  >  News  >  Investor News  >  2007